Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding cangrelor.

@article{Lhermusier2015OverviewOT,
  title={Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding cangrelor.},
  author={Thibault Lhermusier and Nevin C. Baker and Ron Waksman},
  journal={The American journal of cardiology},
  year={2015},
  volume={115 8},
  pages={1154-61}
}
Landmark clinical trials have established the benefit of P2Y12 inhibitors in the setting of acute coronary syndrome and percutaneous coronary intervention. On February 12, 2014, the Medicines Company (Sponsor) presented efficacy and safety data regarding cangrelor to the Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee. The Sponsor sought approval for 2 indications: (1) in the setting of percutaneous coronary intervention for the reduction of thrombotic… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 30 references

and Drug Administration

US Foo
FDA Briefing Document for the Cardiovascular andRenal DrugsAdvisory Committee. Presented February 12, 2014, at Silver Spring, MD. Available at: http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/UCM385234.pdf. Accessed on F • 2015
View 11 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…